The simple answer is we've only seen data on 21 patients that I am aware of.
I have to admit that had always been very discouraging to me because Dr Youssef, at Methodist, had worked with Said in the past trial on ARDS. It's always left me wondering why we were only seeing his work and was it placebo effect because he is a believer in VIP.
If they are indeed seeing these results in 150 patients, that would be fantastic news, and I can't wait until additional info is released. There has to be other investors like me that want to see more data on more patients than just Youssef's before going 'all in'.